FI991187A7 - Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina - Google Patents

Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina Download PDF

Info

Publication number
FI991187A7
FI991187A7 FI991187A FI991187A FI991187A7 FI 991187 A7 FI991187 A7 FI 991187A7 FI 991187 A FI991187 A FI 991187A FI 991187 A FI991187 A FI 991187A FI 991187 A7 FI991187 A7 FI 991187A7
Authority
FI
Finland
Prior art keywords
pde
amides
tnf inhibitors
immunotherapeutic
imides
Prior art date
Application number
FI991187A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI991187A0 (fi
FI991187L (fi
Inventor
Mary Shire
George W Muller
David I Stirling
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of FI991187A0 publication Critical patent/FI991187A0/fi
Publication of FI991187L publication Critical patent/FI991187L/fi
Publication of FI991187A7 publication Critical patent/FI991187A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI991187A 1996-12-03 1997-12-03 Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina FI991187A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/759,788 US5703098A (en) 1994-12-30 1996-12-03 Immunotherapeutic imides/amides
PCT/US1997/022369 WO1998024763A2 (en) 1996-12-03 1997-12-03 Immunotherapeutic imides/amides as pde iv and tnf inhibitors

Publications (3)

Publication Number Publication Date
FI991187A0 FI991187A0 (fi) 1999-05-25
FI991187L FI991187L (fi) 1999-07-16
FI991187A7 true FI991187A7 (fi) 1999-07-16

Family

ID=25056962

Family Applications (1)

Application Number Title Priority Date Filing Date
FI991187A FI991187A7 (fi) 1996-12-03 1997-12-03 Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina

Country Status (13)

Country Link
US (1) US5703098A (enExample)
EP (1) EP0942902A2 (enExample)
JP (1) JP2001506611A (enExample)
KR (1) KR20000069374A (enExample)
CN (1) CN100372836C (enExample)
AU (1) AU735540B2 (enExample)
CA (1) CA2273002A1 (enExample)
FI (1) FI991187A7 (enExample)
HU (1) HUP0000232A3 (enExample)
NZ (1) NZ336713A (enExample)
RU (1) RU2177471C2 (enExample)
SK (1) SK73299A3 (enExample)
WO (1) WO1998024763A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5929117A (en) * 1996-08-12 1999-07-27 Celgene Corporation Immunotherapeutic agents
AU7449698A (en) * 1997-05-21 1998-12-11 Medion Research Laboratories Inc. Therapeutic agents for respiratory diseases
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
HRP20020158B1 (en) 1999-08-21 2007-08-31 Altana Pharma Ag Action of synergistic combination
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20050148034A1 (en) * 2002-04-12 2005-07-07 Hariri Robert J. Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
AU2003262187A1 (en) * 2002-04-12 2003-10-27 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
NZ536908A (en) 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
BR0315316A (pt) * 2002-10-15 2005-08-16 Celgene Corp Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US7354948B2 (en) 2002-11-06 2008-04-08 Celgene Corporation Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
JP2006507324A (ja) * 2002-11-06 2006-03-02 セルジーン・コーポレーション 骨髄増殖性疾患を治療および管理するための選択的サイトカイン阻害薬を含む組成物およびその使用法
CN1738613A (zh) * 2002-11-18 2006-02-22 细胞基因公司 包含(+)－3－(3,4－二甲氧基－苯基)－3－(1－氧代－1,3－二氢－异吲哚－2－基)－丙酰胺的组合物及其使用方法
EP1569599A2 (en) * 2002-11-18 2005-09-07 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP1624893A2 (en) * 2003-04-01 2006-02-15 Applied Research Systems ARS Holding N.V. Inhibitors of phosphodiesterases in infertility
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
EP1692128A1 (en) 2003-11-19 2006-08-23 Signal Pharmaceuticals LLC Indazole compounds and methods of use thereof as protein kinase inhibitors
ZA200609228B (en) * 2004-04-23 2008-05-28 Celgene Corp Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP1811992A2 (en) * 2004-10-28 2007-08-01 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
CA2718412A1 (en) * 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US20120149716A1 (en) 2009-02-10 2012-06-14 Zeldis Jerome B Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
CN102639498A (zh) * 2009-10-09 2012-08-15 细胞基因公司 制备2-(1-苯乙基)异吲哚啉-1-酮化合物的方法
US9408831B2 (en) 2010-04-07 2016-08-09 Celgene Corporation Methods for treating respiratory viral infection
CN103026229B (zh) 2010-06-15 2016-03-30 细胞基因公司 用于治疗银屑病的生物标志物
EP2601950A1 (en) * 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
EP3142663A1 (en) 2014-05-16 2017-03-22 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2628425B1 (fr) * 1988-03-08 1992-04-03 Rhone Poulenc Sante Derives d'isoindolinone, leurs procedes de preparation et les medicaments les contenant
RU2015966C1 (ru) * 1991-06-27 1994-07-15 Киевский университет им.Т.Г.Шевченко Способ получения алкил-(не)замещенных 2-[4-(1-оксо-2-изоиндолинил)фенил]уксусных кислот или их нитрилов
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles

Also Published As

Publication number Publication date
WO1998024763A2 (en) 1998-06-11
CN100372836C (zh) 2008-03-05
AU5594598A (en) 1998-06-29
HUP0000232A3 (en) 2000-10-30
AU735540B2 (en) 2001-07-12
EP0942902A2 (en) 1999-09-22
CA2273002A1 (en) 1998-06-11
SK73299A3 (en) 1999-12-10
US5703098A (en) 1997-12-30
WO1998024763A3 (en) 1998-08-06
CN1254333A (zh) 2000-05-24
HUP0000232A2 (hu) 2000-09-28
FI991187A0 (fi) 1999-05-25
JP2001506611A (ja) 2001-05-22
FI991187L (fi) 1999-07-16
RU2177471C2 (ru) 2001-12-27
NZ336713A (en) 2001-02-23
KR20000069374A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
FI991187A0 (fi) Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina
FI972709A7 (fi) Substituoituja imideja TNF-inhibiittoreina
FI980776L (fi) Sukkinimidi ja maleimidi sytokiini-inhibiittoreita
NO991433D0 (no) Heterosykliske estere og amider
PL331047A1 (en) Novel amidinic derivatives and their application as inhibitors of thrombosin
IL128914A0 (en) Heteroaryl succinamides and their use as metalloproteinase inhibitors
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
DK0929528T3 (da) Aralkyl- og aralkylidenheterocycliske lactamer og imider
DK0934301T3 (da) Aminothiophencarboxylsyreamider og anvendelse deraf som phosphodiesteraseinhibitorer
IL122186A (en) Heterocycles as inhibitors of leucotype adhesion and as vla-4-antagonists
HUP9903974A3 (en) Substituted pyridine derivatives as selective cyclooxigenase-2 inhibitors and use thereof
EP0831800A4 (en) ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THEIR USE AS FACTOR Xa INHIBITORS
AU6803594A (en) Phenylcyclopropane compounds and their use as camp and tnf inhibitors
ZA973804B (en) Substituted indazole derivatives and related compounds
CZ174399A3 (cs) Derivát benzamidu substituovaný heterocyklickými skupinami a jeho použití
PL337645A1 (en) Novel amidine derivatives and their application as thrombosin inhibitors
PL331920A1 (en) Spirocyclic inhibitors of metaloproteases
PL335378A1 (en) Derivatives of inverse hydroxamates as metaloprotease inhibitors
EP0960201A4 (en) RIBONUCLEAS INHIBITORS FROM MAMMALS AND THEIR USE
ZA9811346B (en) Substituted heterocyclic benzocycloalkenes and their use as an analgesic
ZA976611B (en) Pyranoindole and carbazole inhibitors of cox-2
AU1809595A (en) Phenylpyrrole derivatives and their use as dopamine d3 antagonists
AU7222196A (en) Azetidinones and their therapeutic use as cytokine inhibitors
NO932638L (no) 21-klor-pregnanderivat og fremgangsmaater for dets fremstilling

Legal Events

Date Code Title Description
FD Application lapsed